Page 360 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

338 PART III Therapeutic Modalities for the Cancer Patient

42. Piersen CE: Phytoestrogens in botanical dietary supplements: 63. Ohwada S, Ikeya T, Yokomori T: Adjuvant immunochemother-
Implications for cancer, Integr Cancer Ther 2:120–136, 2003. apy with oral Tegafur/Uracil plus PSK in patients with stage II or
43. Meijerman I, Beijnen JH, Schellens JHM: Herb-drug interactions III colorectal cancer: a randomised controlled study, Br J Cancer
VetBooks.ir in oncology: focus on mechanisms of induction, The Oncologist 64. Sakamoto J, Morita S, Oba K, et al.: Efficacy of adjuvant immu-
90:1003–1010, 2004.
11:742–752, 2006.
44. He SM, Yang AK, Li XT, et al.: Effects of herbal products on the
metabolism and transport of anticancer agents, Expert Opin Drug nochemotherapy with polysaccharide K for patients with curatively
resected colorectal cancer: a meta-analysis of centrally randomized
Metab Toxicol 6:1195–1213, 2010. controlled clinical trials, Cancer Immunol Immunother 55:404–411,
45. Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ: Under- 2006.
standing drug interactions with St. John’s wort (Hypericum perfo- 65. Wong LYE, Fai CK, Leung PC: Efficacy of Yun Zhi (Coriolus ver-
ratum L.): impact of hyperforin content, J Pharm Pharmcol, 2018. sicolor) on survival in cancer patients: systematic review and meta-
[Epub ahead of print]. analysis, Recent Pat Inflamm Allergy Drug Discov 6:78–87, 2012.
46. Haefeli WE, Carls A: Drug interactions with phytotherapeutics in 66. Cienki JJ, Zaret L: An internet misadventure: bloodroot salve toxic-
oncology, Expert Opin Drug Metab Toxicol 10:359–377, 2014. ity, J Alt Comp Med 16:1125–1127, 2010.
47. Zhao Q, Wei J, Zhang H: Effects of quercitin on the pharmacoki- 67. Childress MO, Burgess RC, Holland CH, et al.: Consequences of
netics of losartan and its metabolite EXP3174 in rats, Xenobiotica intratumoral injection of a herbal preparation containing blood
1–6, 2018. [Epub ahead of print]. root (Sanguinaria canadensis) extract in two dogs, J Am Vet Med
48. Andersen MR, Sweet E, Zhou M, et al.: Complementary and alter- Assoc 239:374–379, 2011.
native medicine use by breast cancer patients at time of surgery 68. Sun M, Lou W, Chun JY, et al.: Sanguinarine suppresses pros-
which increases the potential for excessive bleeding, Integr Cancer tate tumor growth and inhibits survivin expression, Genes Cancer
Ther 14:119–124, 2015. 1:283–292, 2010.
49. Griessmayr PC, Gautheir M, Barber LG, et al.: Mushroom-derived 69. Ahmad N, Gupta S, Husain MM, et al.: Differential antiprolifera-
maitake PET fraction as a single agent for the treatment of lym- tive and apoptotic response of sanguinarine for cancer cells versus
phoma in dogs, J Vet Intern Med 21:1409–1412, 2007. normal cells, Clin Cancer Res 6:1524–1528, 2000.
50. Peck P: ACP: Garlic, ginseng, ginkgo biloba, and ginger all bad actors 70. Dee R: Dr. Andrew Weil Treats His Dog’s Tumor. June 18, 2015. Available
with coumadin, MedPage Today, 2006. Available at: https://www. at: https://www.bloodrootsalve.com/andrew-weil/. (Accessed 11.02.18).
medpagetoday.com/meetingcoverage/acp/3050. (Accessed 17.07.18). 71. Dr.Weil.com: Web site Bloodroot for skin cancer? January 9, 2006.
51. Memorial Sloan Kettering Cancer Center Web site: About Herbs, Available at: https://www.drweil.com/health-wellness/body-mind-
Botanicals, and Other Products. Available at: https://www.mskcc. spirit/cancer/bloodroot-for-skin-cancer/. Accessed 11.02.18.
org/cancer-care/diagnosis-treatment/symptom-management/ 72. Hostanska K, Daum G, Saller R: Cytostatic and apoptosis-inducing
integrative-medicine/herbs. (Accessed 11.02.18). activity of boswellic acids toward malignant cell lines in vitro, Anti-
52. DiNatale C: Clinical application of Chinese herbal medicine for cancer Res 22:2853–2862, 2002.
companion animals. In Xie H, Preast V, editors: Xie’s Chinese veteri- 73. Roy S, Khanna S, Krishnaraju AV, et al.: Regulation of vascular
nary herbology, Ames, 2010, Blackwell Publishing. responses to inflammation: inducible matrix metalloproteinase-3
53. Yap KY, Kuo EY, Lee JJ, et al.: An onco-informatics database for expression in human microvascular endothelial cells is sensitive
anticancer drug interactions with complementary and alternative to anti-inflammatory boswellia, Antioxid Redox Signal 8:653–660,
medicines used in cancer treatment and supportive care: an overview 2006.
of the OncoRx project, Support Care Cancer 18:883–891, 2010. 74. Chevrier MR, Ryan AE, Lee DYW, et al.: Boswellia carterii extract
54. Chiu J, Yau T, Epstein RJ: Complications of traditional Chinese/ inhibits TH1 cytokines and promotes TH2 cytokines in vitro, Clin
herbal medicines (TCM)—a guide for perplexed oncologists and Diagn Lab Immunol 12:575–580, 2005.
other cancer caregivers, Support Care Cancer 17:231–240, 2009. 75. Pungle P, Banayalikar M, Suthar A, et al.: Immunomodulatory
55. Liu SH, Liu YF, Liou SH, et al.: Mortality and cancer inci- activity of boswellic acids of Boswellia serrata Roxb, Indian J Exp
dence among physicians of traditional Chinese medicine: a 20 Biol 41:1460–1462, 2003.
year national follow-up study, Occup Environ Med 67:166–169, 76. Anthoni C, Laukoetter MG, Rijcken E, et al.: Mechanisms under-
2010. lying the anti-inflammatory actions of boswellic acid derivatives in
56. Yang HY, Wang JD, Lo TC, et al.: Increased mortality risk for can- experimental colitis, Am J Physiol Gastro Liver Physiol 290:G1131–
cers of the kidney and other urinary organs among Chinese herbal- G1137, 2006.
ists, J Epidemiol 19:17–23, 2009. 77. Krieglstein CE, Anthoni C, Rijcken EJM, et al.: Acetyl-11-keto-
57. Mok TSK, Yeo W, Johnson PJ, et al.: A double-blind placebo- beta-boswellic acid, a constituent of a herbal medicine from
controlled randomized study of Chinese herbal medicine as Boswellia serrata resin, attenuates experimental ileitis, Int J Colorec-
complementary therapy for reduction of chemotherapy-induced tal Dis 16:88–95, 2001.
toxicity, Ann Oncol 18:768–774, 2007. 78. Kimmatkar N, Thawani V, Hingorani L, et al.: Efficacy and toler-
58. Guo R, Canter PH, Ernst E: A systematic review of randomized ability of Boswellia serrata extract in treatment of osteoarthritis of
clinical trials of individualized herbal medicine in any indication, knee—a randomized double-blind placebo-controlled trial, Phyto-
Postgrad Med J 83:633–637, 2007. medicine 10:3–7, 2003.
59. Wasser SP: Medicinal mushroom science: current perspectives, 79. Sharma S, Thawani V, Hingorani L, et al.: Pharmacokinetic
advances, evidences, and challenges, Biomed J 37:345–356, 2014. study of 11-keto beta-boswellic acid, Phytomedicine 11:255–260,
60. Hardy ML: Dietary supplement use in cancer care: help or harm, 2004.
Hematol Oncol Clin North Am 22:581–617, 2008. 80. Frank A, Unger M: Analysis of frankincense from various Boswellia
61. Song KS, Kim JS, Jing K, et al.: Protein-bound polysaccharide from species with inhibitory activity on human drug metabolizing
Phellinus linteus inhibits tumor growth, invasion, and angiogenesis cytochrome P450 enzymes using liquid chromatography mass
and alters Wnt/beta-catenin in SW480 human colon cancer cells, spectrometry after automated on-line extraction, J Chromatogr A
BMC Cancer 11:307, 2011. 1112:255–262, 2006.
62. Brown DC, Reetz J: Single agent polysaccharopeptide delays 81. Zhu HL, Ji JL, Huang XF: Curcumin and its formulations: Poten-
metastases and improves survival in naturally occurring hemangio- tial anti-cancer agents, Anticancer Agents Med Chem 12:210–218,
sarcoma, Evid Based Complement Alternat Med 8, 2012. Article ID 2011.
384301.